Alkem MedTech to acquire 55% stake in Occlutech for EUR 99.4M (₹1,074 Cr)
Alkem MedTech will acquire up to 55% of Occlutech Holding AG for EUR 99.4 million (approx. ₹1,074 crore). Occlutech specializes in minimally invasive cardiac implants and reported EUR 49.4 million revenue in CY25. The acquisition is expected to be completed by June 2026.
The acquisition represents a significant strategic expansion into a new, high-value market segment (cardiovascular devices) with global potential, indicating a substantial impact on Alkem's business diversification and future growth trajectory.
The acquisition of a majority stake in Occlutech by Alkem MedTech is a strategic move to expand into the advanced cardiovascular devices market, which is viewed positively for future growth.
Alkem MedTech Pvt Ltd, a subsidiary of Alkem Laboratories Ltd, has announced its strategic intent to acquire a majority stake of up to 55% in Occlutech Holding AG, a Switzerland-based global medical devices company specializing in minimally invasive cardiac implants. The acquisition consideration is set at EUR 99.4 million, approximately ₹1,074 crore, and is subject to statutory approvals and definitive agreements.
This move marks a significant step for Alkem MedTech in expanding its global footprint and entering the advanced cardiovascular devices market. Occlutech, the second-largest company in Europe and third-largest globally in its segment, develops, manufactures, and commercializes medical devices for congenital heart disease, stroke prevention, and heart failure. In calendar year 2025, Occlutech reported unaudited revenues of EUR 49.4 million, with approximately 85% of its revenue generated from Europe and the US.
B. N. Singh, Executive Chairman of Alkem Laboratories, stated that the acquisition aligns with Alkem's long-term vision of becoming a global player in the medical devices industry. Kaustav Banerjee, CEO of Alkem MedTech, highlighted Occlutech's established capabilities and experienced management team as a strong foundation for growth in the cardiology segment. Tor Peters, CEO of Occlutech, expressed confidence in leveraging Alkem's capabilities to support the company's next growth phase, anticipating cost optimization synergies.
The transaction is expected to be completed by June 2026, pending regulatory approvals and the fulfillment of other conditions precedent. The Boston Consulting Group (BCG) acted as an advisor for this transaction.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.